← Solventum overview

Solventum vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Solventum Corp. (SOLV)

Q3 2026
▲3▼1

Solventum's strong Q2, raised guidance, and planned Health Information Systems spin-off drive gains

  • Q2 beat and raised 2026 guidance Solventum reported Q2 adjusted EPS of $2.55, beating estimates by 33.5%, and revenue of $2.21 billion, up 2.2%. Management raised full-year 2026 organic sales growth and adjusted EPS guidance, signaling stronger-than-expected business momentum. This directly boosts investor confidence and the stock price.

    This is the core positive event that drove the stock higher this period.

  • Health Information Systems separation announced Solventum plans to separate its Health Information Systems unit, a $1.4 billion software business, to become a more focused MedTech company. The move is expected to unlock shareholder value and let each business grow faster. Investors often reward such spin-offs with a higher stock price.

    This strategic move is a major new catalyst for the stock.

  • Cost savings and margin expansion on track Solventum targets about $500 million in annual cost savings from its Transform for the Future program, with most benefits coming in 2027 and beyond. It still expects 50-100 basis points of operating margin expansion in 2026 despite tariffs. This supports future earnings growth.

    Cost savings underpin profitability and are a key part of the bullish case.

  • Potential 2027 raw material cost hike from 3M Under its supply agreement, 3M can raise prices for certain raw materials in 2027, which could cut Solventum's profit margin by about 100 basis points. The company is working on alternatives, but this remains a risk that could weigh on the stock.

    This is a real counterweight that could pressure future profits.

August 2026
▲3▼1

Solventum's strong Q2, raised guidance, and planned Health Information Systems spin-off drive gains

  • Q2 beat and raised 2026 guidance Solventum reported Q2 adjusted EPS of $2.55, beating estimates by 33.5%, and revenue of $2.21 billion, up 2.2%. Management raised full-year 2026 organic sales growth and adjusted EPS guidance, signaling stronger-than-expected business momentum. This directly boosts investor confidence and the stock price.

    This is the core positive event that drove the stock higher this period.

  • Health Information Systems separation announced Solventum plans to separate its Health Information Systems unit, a $1.4 billion software business, to become a more focused MedTech company. The move is expected to unlock shareholder value and let each business grow faster. Investors often reward such spin-offs with a higher stock price.

    This strategic move is a major new catalyst for the stock.

  • Cost savings and margin expansion on track Solventum targets about $500 million in annual cost savings from its Transform for the Future program, with most benefits coming in 2027 and beyond. It still expects 50-100 basis points of operating margin expansion in 2026 despite tariffs. This supports future earnings growth.

    Cost savings underpin profitability and are a key part of the bullish case.

  • Potential 2027 raw material cost hike from 3M Under its supply agreement, 3M can raise prices for certain raw materials in 2027, which could cut Solventum's profit margin by about 100 basis points. The company is working on alternatives, but this remains a risk that could weigh on the stock.

    This is a real counterweight that could pressure future profits.

Latest
▲3▼1

Solventum's strong Q2, raised guidance, and planned Health Information Systems spin-off drive gains

  • Q2 beat and raised 2026 guidance Solventum reported Q2 adjusted EPS of $2.55, beating estimates by 33.5%, and revenue of $2.21 billion, up 2.2%. Management raised full-year 2026 organic sales growth and adjusted EPS guidance, signaling stronger-than-expected business momentum. This directly boosts investor confidence and the stock price.

    This is the core positive event that drove the stock higher this period.

  • Health Information Systems separation announced Solventum plans to separate its Health Information Systems unit, a $1.4 billion software business, to become a more focused MedTech company. The move is expected to unlock shareholder value and let each business grow faster. Investors often reward such spin-offs with a higher stock price.

    This strategic move is a major new catalyst for the stock.

  • Cost savings and margin expansion on track Solventum targets about $500 million in annual cost savings from its Transform for the Future program, with most benefits coming in 2027 and beyond. It still expects 50-100 basis points of operating margin expansion in 2026 despite tariffs. This supports future earnings growth.

    Cost savings underpin profitability and are a key part of the bullish case.

  • Potential 2027 raw material cost hike from 3M Under its supply agreement, 3M can raise prices for certain raw materials in 2027, which could cut Solventum's profit margin by about 100 basis points. The company is working on alternatives, but this remains a risk that could weigh on the stock.

    This is a real counterweight that could pressure future profits.

Integer Holdings Corp (ITGR)

Q3 2026
▲1▼1

KKR's $127/share buyout drives ITGR, with approval risk remaining

  • KKR buyout at $127 per share KKR agreed to buy Integer for $127 per share in cash, a $5.7 billion deal at a 51.8% premium. The stock now trades near the offer, so price reflects the deal, not company performance.

    This is the dominant new event that now defines ITGR's stock price.

  • Deal approval still pending Financing is secured, but the deal still needs shareholder and regulatory approval. Analysts downgraded to neutral, and fair-value estimates of $112–$139 sit around the offer, showing limited upside unless a higher bid emerges.

    It explains the main remaining risks and why the stock trades near the offer.

  • Weak Q2 results and withdrawn guidance Q2 profit fell to $23.6 million from $37 million, revenue slipped 2.6%, and gross margin narrowed to 24.3%. Management withdrew guidance and canceled its earnings call, removing forward-looking data for investors.

    It is the key counterweight showing underlying business weakness behind the deal.

  • Investor-rights review may seek higher bid An investor-rights law firm is reviewing whether $127 is fair and may seek a higher bid. This creates a small chance of a bump, but also adds uncertainty around the deal's final price.

    It highlights a potential upside catalyst and a source of deal uncertainty.

August 2026
▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

  • KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.

    The buyout is the single force now setting ITGR's price and the main answer to why it moves.

  • Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.

    It is the main negative fundamental fact and the real counterweight to the buyout.

  • Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.

    It explains why ordinary operating news no longer drives the stock and why the deal dominates.

  • Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.

    It is the only new event that could change the deal price, so it matters to the buyout story.

Latest
▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

  • KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.

    The buyout is the single force now setting ITGR's price and the main answer to why it moves.

  • Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.

    It is the main negative fundamental fact and the real counterweight to the buyout.

  • Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.

    It explains why ordinary operating news no longer drives the stock and why the deal dominates.

  • Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.

    It is the only new event that could change the deal price, so it matters to the buyout story.

July 2026
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.